1,048 Companies

Access all companies

Find technology partners quickly.

Spotfolio tracks over one million companies in technology industries.

There are 1,048 companies in the field of Biopharma on spotfolio that produce or deliver products, that utilize or research technologies or that are otherwise engaged in topics such as Clinical, Drug, Disease, Patients, Treatment, Research, Therapeutic, Pharmaceutical .

Start-ups (184)

Early-stage companies (270)

Established companies (511)

The majority of these companies is located in the following countries.

United States (538)

United Kingdom (82)

Canada (51)

China (46)

Example Companies

Find companies in your area

Alsonex Alsonex Pty Ltd

early-stage

Access

  • Technologies
  • Core data such as location, employees, revenues
  • Similar and peer companies
  • and more

Web Quotes

for Motor Neuron Disease Alsonex is focused on developing new treatments for neurodegenerative disease such as Motor Neuron Disease. The company was founded ...

the cause of neuroinflammation and its role in causing neurodegenerative disease. At Alsonex, we are committed to being a part of the solution to slowing ...

neurodegenerative diseases such as Parkinson’s Disease, Alzheimer’s Disease, Huntington’s Disease and Motor Neuron Disease. So if you’re interested in additional ...

impact on the significant challenges faced by people with neurodegenerative disease. Contact information Address: 210 Alice Street Brisbane, QLD 4000 +

News - Contact News Alsonex New approach to treating Neurodegenerative Disease Alsonex is a drug development company dedicated to developing new treatments ...

are urgently required to help slow the progression of neurodegenerative disease and it remains an area of intensive research within the pharmaceutical industry ...

will slow the disease and improve quality of life for sufferers. New research is increasing our understanding of the factors that drive disease progression ...

neurodegenerative diseases such as Parkinson’s Disease, Alzheimer’s Disease, Huntington’s Disease and Motor Neuron Disease. Read More News The search for a viable ...

neurodegenerative disease and although our first interest is in MND, we have an expanding interest in Parkinson's Disease and Alzheimer's Disease. Read More ...

Alsonex is a biotech company creating treatments for motor neurone disease and other neurodegenerative disorders. Inquiries: info@alsonex.com.au Read

Access

  • Technologies
  • Core data such as location, employees, revenues
  • Similar and peer companies
  • and more

Web Quotes

and animal models of disease, with the goal of using the knowledge gained to develop innovative new therapies for kidney disease. Research projects span ...

treatments in animal models of disease, and the examination of structure-function relationships in patients with kidney disease. Share by:

specific disease pathways, Dr. Wrana believes cancer involves a complex network of pathways that work together to misregulate cells and cause disease. His ...

networks and to reveal new targets for treatments that would attack the entire disease network, not just individual hubs. Dr. Wrana's research program involves

Neuropore Therapies Neuropore Therapies, Inc

established

Access

  • Technologies
  • Core data such as location, employees, revenues
  • Similar and peer companies
  • and more

Web Quotes

Volunteers with NPT520-34, a Therapeutic Candidate Aimed at Treating Parkinson's Disease and Amyotrophic Lateral Sclerosis Neuropore Completes Phase 1 Clinical ...

Volunteers with NPT520-34, a Therapeutic Candidate Aimed at Treating Parkinson's Disease and Amyotrophic Lateral Sclerosis (Business Wire Article) SAN DIEGO, January ...

NPT520-34. NPT520-34 is a small molecule being developed for Parkinson’s disease and amyotrophic lateral sclerosis. The Phase 1 study was designed to evaluate ...

small molecule therapeutic opportunity for patients living with Parkinson’s disease and amyotrophic lateral sclerosis. NPT520-34 proved to be safe and tolerable ...

and patient population for the next study.” About Parkinson's Disease Parkinson’s disease (PD) is a debilitating neurodegenerative disorder afflicting ...

managing the early motor symptoms of the disease, mainly through the use of levodopa or dopamine agonists. As the disease progresses and dopaminergic neurons

Enabling IND Phase 1 Phase 2 Neuroinflammation: NPT520-34: Parkinson's Disease NPT520-34: Amyotrophic Lateral Sclerosis (Orphan Drug Designation by FDA) ...

Lateral Sclerosis NPT1220-312: Parkinson's Disease 2nd Generation: Rare Disease Autophagy NPT520-337: Rare Disease (PI3K inhibitor (MA)) New Targets α-synuclein ...

α-synuclein Oligomerization Inhibitor UCB0599: Parkinson's Disease mailto:info@neuropore.com MA = macroautophagy; CMA = chaperone-mediated autophagy; MIT ...

Parkinson’s disease Neuropore Therapies is currently advancing two exciting novel therapeutic candidates (NPT520-34 and NPT1220-312) as disease-modifying ...

effects on neuropathology and motor function in animal models of Parkinson’s disease. NPT520-34 also reduces the expression of markers of neuroinflammation and ...

in animal models of amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease. NPT520-34 completed Phase 1 clinical studies in healthy volunteers in 2019

Cue Biopharma Cue Biopharma, Inc.

early-stage

Access

  • Technologies
  • Core data such as location, employees, revenues
  • Similar and peer companies
  • and more

Web Quotes

Publications - Pipeline - Overview - Immuno-Oncology - Infectious Disease - Autoimmune Disease - Clinical Trials - CUE-101-01 HPV16+ HEAD AND NECK CANCER ...

- Partnering - Careers - Overview - Current Openings Autoimmune Disease - About Us - Overview - Leadership - Founders - Board of Directors ...

Publications - Pipeline - Overview - Immuno-Oncology - Infectious Disease - Autoimmune Disease - Clinical Trials - CUE-101-01 HPV16+ HEAD AND NECK CANCER ...

broad range of addressable autoimmune diseases by selectively modulating disease-associated T cells so that healthy cells are protected from immune attack ...

without compromising the immune system. Immuno-STATs inhibit autoimmune disease-associated T cells via two general strategies: - Inhibition of autoreactive ...

Overview Pipeline - Overview - Immuno-Oncology - Infectious Disease - Autoimmune Disease Investors - Overview - News Releases - Stock Information -

Publications - Pipeline - Overview - Immuno-Oncology - Infectious Disease - Autoimmune Disease - Clinical Trials - CUE-101-01 HPV16+ HEAD AND NECK CANCER ...

Publications - Pipeline - Overview - Immuno-Oncology - Infectious Disease - Autoimmune Disease - Clinical Trials - CUE-101-01 HPV16+ HEAD AND NECK CANCER ...

prevailing immunotherapeutics, via direct engagement with and modulation of disease-associated T cells in a patient’s body. Immuno-Oncology CUE-100 Series ...

CUE-102 (WT1 / IL-2) CUE-103 (Undisclosed / IL-2) Chronic Infectious Disease CUE-200 Series - MHC Class I / CD80 and 4-1BBL Drug Discovery Optimization ...

Optimization IND-Enabling Phase I Development Partner CUE-201 Autoimmune Disease CUE-300 Series - MHC Class I & II / Undisclosed Drug Discovery Optimization ...

Overview Pipeline - Overview - Immuno-Oncology - Infectious Disease - Autoimmune Disease Investors - Overview - News Releases - Stock Information -

Xortx Therapeutics Xortx Therapeutics Inc.

Access

  • Technologies
  • Core data such as location, employees, revenues
  • Similar and peer companies
  • and more

Web Quotes

Coronavirus – COVID-19 Program - Autosomal Dominant Polycystic Kidney Disease - Diabetic Nephropathy - Strategic Partnerships - Investors - Press ...

focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce that Dr. Allen Davidoff, CEO, will be presenting ...

redefining how kidney disease is treated. The presentation outlines the critical issues facing millions of patients with progressive kidney disease due to diabetes ...

diabetes, diabetic nephropathy and polycystic kidney disease and the compelling studies and mounting evidence confirming XORTX’s approach. Company Highlights ...

develop treatments for progressive kidney disease due to diabetes, diabetic nephropathy and polycystic kidney disease - XORTX’s XRx-008 (a proprietary reformulation ...

drug development program to treat autosomal dominant polycystic kidney disease (ADPKD) - TMX-049, is a late phase 2b stage program to treat type 2 diabetic

Coronavirus – COVID-19 Program - Autosomal Dominant Polycystic Kidney Disease - Diabetic Nephropathy - Strategic Partnerships - Investors - Press ...

Contact Site Search XORTX Highlights New Research on Polycystic Kidney Disease Awareness Day - September 4, 2019 - by aaronbb ● New Study Shows a Novel ...

therapies to treat progressive kidney disease, is pleased to highlight in conjunction with Polycystic Kidney Disease Awareness Day, a new, eloquent research ...

oxalate crystals form in the kidneys of individuals with polycystic kidney disease. For the first time this research identifies a new pathway for accelerated ...

progression of autosomal dominant polycystic kidney disease (ADPKD) in individuals with progressing kidney disease. Accumulating evidence over the past decade ...

accelerated progression of kidney injury and cyst growth. The mechanism of disease action for uric acid is considered to be due to a combination of blood vessel

Use detailed technology terms.

Only spotfolio allows for searching with detailed technology terms, as we provide you with all topics that technology companies talk about.

Use Cases

Register now

Why Technology Scouting?

Technology scouting is the basis for your innovation management, identifies new technological developments as early as possible and protects you from disruptive business models.

Identify technology partners

Boost your market research

Look beyond major players

Build long and short lists

Collect technology leaders, providers, start ups and potential new partners in lists via simple tagging to take further steps with your team.